This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Smoking
and you are
between 18 and 60
years old
Phase
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of this study is to examine whether doxazosin will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking daily smokers. Participants will participate in a smoking cessation attempt after the laboratory sessions.

Provided treatments

  • Drug: Doxazosin 4mg/day
  • Drug: Placebo
  • Drug: Doxazosin 8mg/day
Tris trial is registered with FDA with number: NCT01730846. The sponsor of the trial is Yale University and it is looking for 35 volunteers for the current phase.
Official trial title:
Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?